Stock listing

NASDAQ:ALLR Allarity Therapeutics, Inc. Stock

Home listing (NASDAQ) of Allarity Therapeutics, Inc.

Follow Allarity Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:ALLR

$0.785 USD -0.087 (-10.0%)

Close on Nov 20, 2026

Past year -20.9% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.780 – $0.891 USDNov 20, 2026
Volume
305,151 sharesNov 20, 2026
Market cap
$12.56M USDAt the close on Nov 20, 2026 · price × 16.00M shares outstanding
52-week range
$0.769 – $1.840 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$133,763 USDMedian day 108,498 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Allarity Therapeutics, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ALLR · Home$0.785 USD-0.087 (-10.0%)305,151$0.840$0.891$0.780$0.872Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ALLR · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.785-0.087-10.0%$0.840$0.891$0.780305,151
$0.872+0.031+3.7%$0.845$0.899$0.840290,796
$0.841-0.034-3.9%$0.879$0.889$0.818213,175
$0.875-0.079-8.2%$0.950$0.965$0.865196,914
$0.954+0.040+4.4%$0.930$0.999$0.880279,178
$0.914-0.022-2.3%$0.931$0.970$0.88077,798
$0.935+0.025+2.8%$0.910$0.956$0.89097,139
$0.910-0.033-3.5%$0.940$0.985$0.90782,871
$0.943-0.022-2.3%$0.970$1.000$0.93073,898
$0.965-0.011-1.1%$0.960$0.990$0.96064,280
$0.976-0.104-9.6%$1.090$1.100$0.950155,324
$1.080-0.050-4.4%$1.150$1.180$1.070135,808
$1.130+0.152+15.6%$0.980$1.130$0.980320,357
$0.978+0.107+12.3%$0.874$1.030$0.874166,742
$0.870-0.020-2.2%$0.890$0.905$0.850176,267
$0.890-0.060-6.3%$0.938$0.938$0.854150,036
$0.950+0.030+3.3%$0.930$0.959$0.91069,802
$0.920+0.005+0.5%$0.930$0.960$0.900136,055
$0.915+0.050+5.7%$0.873$0.958$0.870174,219
$0.865+0.019+2.2%$0.842$0.896$0.84070,570
$0.847-0.033-3.8%$0.880$0.880$0.83290,822
$0.880+0.004+0.4%$0.873$0.902$0.84088,643
$0.876+0.003+0.3%$0.890$0.908$0.870108,498
$0.873-0.022-2.5%$0.898$0.915$0.82186,465
$0.895+0.062+7.5%$0.871$0.920$0.821232,063
$0.833-0.041-4.6%$0.897$0.900$0.800323,178
$0.873+0.003+0.4%$0.882$0.890$0.86064,077
$0.870+0.010+1.2%$0.880$0.910$0.830111,400
$0.860-0.130-13.1%$0.970$0.990$0.832415,200
$0.990+0.008+0.8%$0.995$1.040$0.99097,000
$0.982-0.002-0.2%$0.995$1.000$0.95063,500
$0.984-0.001-0.1%$1.020$1.040$0.98181,000
$0.985-0.015-1.5%$0.983$1.000$0.98045,300
$1.000-0.040-3.8%$1.040$1.050$0.99039,100
$1.0400.0000.0%$1.055$1.080$1.03028,900
$1.040-0.010-1.0%$1.060$1.079$1.01074,100
$1.050+0.085+8.8%$0.989$1.078$0.968119,100
$0.965-0.003-0.3%$0.972$1.000$0.940167,600
$0.968-0.062-6.0%$1.030$1.083$0.901270,900
$1.030-0.060-5.5%$1.090$1.100$1.03043,700
$1.090+0.050+4.8%$1.060$1.090$1.03075,000
$1.040-0.070-6.3%$1.150$1.150$1.010167,500
$1.110-0.060-5.1%$1.170$1.230$1.100182,900
$1.170-0.040-3.3%$1.200$1.200$1.130114,900
$1.210+0.050+4.3%$1.150$1.220$1.110185,600
$1.160+0.005+0.4%$1.130$1.267$1.130160,400
$1.155+0.045+4.1%$1.130$1.200$1.11053,500
$1.110-0.060-5.1%$1.160$1.195$1.090154,500
$1.170-0.050-4.1%$1.200$1.230$1.170112,600
$1.220-0.030-2.4%$1.320$1.340$1.210205,200
$1.250-0.012-1.0%$1.290$1.350$1.22079,300
$1.262+0.012+1.0%$1.280$1.290$1.25065,300
$1.250-0.170-12.0%$1.360$1.374$1.250236,600
$1.420-0.010-0.7%$1.440$1.450$1.40054,500
$1.430+0.020+1.4%$1.430$1.480$1.39043,800
$1.410-0.010-0.7%$1.450$1.490$1.370124,000
$1.420+0.010+0.7%$1.410$1.430$1.37054,000
$1.4100.0000.0%$1.410$1.440$1.320106,300
$1.410+0.030+2.2%$1.380$1.460$1.350139,600
$1.380+0.040+3.0%$1.350$1.430$1.34049,800
$1.340+0.010+0.8%$1.360$1.410$1.34044,600
$1.330-0.060-4.3%$1.380$1.410$1.33057,919
$1.390-0.030-2.1%$1.420$1.420$1.37032,852
$1.420-0.010-0.7%$1.410$1.492$1.380111,700
$1.4300.0000.0%$1.410$1.490$1.39078,600

Splits

4 splits since 2023 · NASDAQ:ALLR · every price before a split is adjusted for it

DayRatioWhat
1-for-30Consolidation
1-for-20Consolidation
1-for-40Consolidation
1-for-35Consolidation
Ticker
NASDAQ:ALLR
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Allarity Therapeutics, Inc. news

Allarity Therapeutics, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
22 in the last 12 months · 109 in all · newest Nov 18, 2026 · oldest 2022
Decks
13 decks · latest May 8, 2026

Where Allarity Therapeutics, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ALLR · Home listing · This pageNASDAQUnited StatesUSD
BOATS:ALLRBOATSUnited StatesUSD

Valuation

EV/sales 61.4× against a median of 7.5×: the highest of 4 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$21.48M USD
P/E
Loss
EV/sales
61.4×
EV/EBITDA
Negative EBITDA
Price/book
Negative equity
Gross margin
Revenue too small
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
Negative equity
Beta vs S&P 500
1.40

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Allarity Therapeutics, Inc. · NASDAQ:ALLRUS$12.56MUS$21.48Mn/a61.4×n/an/an/an/a1.40
Devonian Health Group, Inc. · TSXV:GSDUS$13.09MUS$12.59Mn/a6.0×n/a2.7×−204.1%0.0×0.12
Bolt Biotherapeutics, Inc. · NASDAQ:BOLTUS$12.80MUS$18.89Mn/a7.5×n/a1.5×n/a2.4×0.52
Avai Bio, Inc. · OTC:AVAIUS$12.79MUS$12.67Mn/an/an/an/an/an/a0.28
Neuphoria Therapeutics Inc. · NASDAQ:NEUPUS$12.72M−US$6.03Mn/an/an/a0.5×n/a0.0×0.61
Seres Therapeutics, Inc. · NASDAQ:MCRBUS$12.64MUS$30.89Mn/a14.5×n/a0.6×n/a1.7×1.21
Passage Bio, Inc. · NASDAQ:PASGUS$12.61M−US$7.55Mn/an/an/a252×n/a0.0×1.94
Lobe Sciences Ltd · CSE:LOBEUS$12.52MUS$8.89Mn/an/an/a9.5×n/a0.0×0.31
Biophytis SA · EURONEXT:ALBPSUS$12.47MUS$19.44Mn/an/an/an/an/an/an/a
MIRA Pharmaceuticals, Inc. · NASDAQ:MIRAUS$12.23MUS$5.26Mn/an/an/a1.8×n/a0.0×1.48
Genflow Biosciences PLC · LSE:GENFUS$12.06MUS$11.23Mn/an/an/a48.5×n/a0.0×n/a
Median of the othersUS$12.63MUS$11.91M7.5×2.2×−204.1%0.0×0.56

Forecasts

1 strong buy · Analysts' consensus from EODHD, read Nov 15, 2026. Not 6ix's view and not investment advice.

Price target
11.00 USD · Analysts' mean
EPS, year to Dec 2026
-0.80 · 1 analyst
Revenue, year to Dec 2026
25K · 1 analyst

Team and board

Officers

OfficerRole
Thomas JensenChief Executive Officer, Board Member
Jeff ErvinChief Financial Officer
Jeremy R. GraffPresident and Chief Development Officer
Steen KnudsenChief Scientific Officer, Founder

Board

DirectorRole
Jerry McLaughlinChairman, Independent Board Member
Jesper HøilandIndependent Board Member
Laura BenjaminIndependent Board Member
Thomas JensenChief Executive Officer, Board Member

Events

QuarterResultsShare move
Q3 2026Nov 13, 2026 · Before open+4.4%
Q2 2026Aug 14, 2026 · Before open+0.7%
Q1 2026May 15, 2026 · After close+5.9%
Q3 2025Nov 14, 2025 · Before open−0.8%
Q2 2025Aug 15, 2025 · After close−5.0%
Q1 2025May 9, 2025−4.7%
Q4 2024Mar 31, 2025−12.5%
Q3 2024Nov 14, 2024 · Before open−2.8%
Q2 2024Aug 5, 2024 · After close−5.8%
Q1 2024May 14, 2024 · After close−13.8%
All 20 quarters
QuarterResultsShare move
Q4 2023Mar 8, 2024 · Before open−0.7%
Q3 2023Nov 14, 2023 · Before open0.0%
Q2 2023Aug 14, 2023 · After close−7.6%
Q1 2023May 11, 2023 · After close−10.0%
Q4 2022Mar 13, 2023 · After close−5.5%
Q3 2022Nov 14, 2022 · After close−9.0%
Q2 2022Aug 22, 2022 · After close−23.7%
Q1 2022May 27, 2022 · After close−1.4%
Quarter to Sep 30, 2021Dec 21, 2021
Quarter to Jun 30, 2021Sep 30, 2021

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (May 2026)Investor deck22 slidesMay 8, 2026
Investor Presentation (May 2025)Investor deck24 slidesMay 2025
Corporate Update (February 2024)Corporate update16 slidesFebruary 2024
Investor Presentation (December 2023)Investor deck45 slidesDec 6, 2023
Investor Presentation (November 2023)Investor deck42 slidesNov 13, 2023
Investor Presentation (March 2023)Investor deck37 slidesMar 9, 2023
Ladenburg Healthcare Conference September 2022Conference23 slidesSep 26, 2022
Investor Presentation (August 2022)Investor deck39 slidesAug 29, 2022
Investor Presentation (May 2022)Investor deck38 slidesMay 27, 2022
Investor Presentation (January 2022)Investor deck40 slidesJan 18, 2022
All 13 decks
DeckKindSlidesDate
Merger or Acquisition (October 2021)Merger or acquisition37 slidesOct 8, 2021
Oncology Venture — Shareholder Meeting (March 2020)Shareholder meeting8 slidesMar 31, 2020
Oncology Venture — Fact Sheet (April 2019)Fact sheet2 slidesApril 2019

Open Decks

Financings

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue320.0K00000120.0K1.46M1.46M143.3K
Cost of revenue9.00K37.0K120.0K106.0K86.0K5.08M2.22M
Gross profit320.0K-9.00K-37.0K-2.27M-106.0K-86.0K120.0K-3.62M-761.5K143.3K
Research and development6.60M6.10M7.10M6.93M14.2M4.22M6.37M
Selling, general and administrative6.32M11.4M10.0M9.96M12.4M4.10M3.87M
Operating income-12.6M-27.2M-17.1M-34.5M-26.6M-8.32M-17.6M-4.98M-3.84M-4.49M
Depreciation and amortization13.0K9.00K37.0K60.0K106.0K46.0K51.0K32.5K8.70K278.2K
EBITDA-12.6M-27.2M-17.1M-34.4M-26.4M-8.27M-17.6M-4.95M-3.83M-4.21M
Interest expense185.0K653.0K498.0K223.0K99.0K93.0K3.31M233.2K2.42K43.7K
Income before tax-11.2M-24.9M-11.8M-17.6M-26.5M-6.42M-19.0M-3.46M-4.99M-4.45M
Income tax0-381.0K83.0K-1.52M133.0K198.0K-4.58M-1.07M-95.1K-766.9K
Net income-11.2M-24.5M-11.9M-16.1M-26.6M-6.62M-14.3M-2.29M-4.90M-3.68M
Earnings per share, basic-0.78-15.65-6,031.31-3,093.42-4.19-2.03
Earnings per share, diluted-10.26-3,093.42-4.19

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents14.7M19.5M166.0K2.03M19.6M298.0K1.52M237.4K536.0K2.07M
Short-term investments72.0K0350.0K
Receivables895.0K2.23M946.0K871.0K1.34M1.12M1.66M10.8M407.7K2.31K
Inventory-1.34M-2.00K168.9K34.7K
Current assets17.9M22.3M1.97M4.97M21.4M1.72M3.34M2.21M1.31M4.37M
Property, plant and equipment330.0K309.0K20.0K21.0K8.00K21.0K2.92M363.0K135.0K
Goodwill1.91M
Total assets18.3M22.6M11.9M14.5M49.6M33.4M31.6M38.6M2.09M6.54M
Accounts payable4.28M4.18M8.42M6.25M698.0K2.12M2.18M1.94M472.4K1.27M
Current liabilities8.43M10.8M14.2M11.2M20.7M5.53M4.72M5.43M1.70M1.34M
Long-term debt1.08M979.0K880.0K
Total debt1.40M1.35M2.69M2.64M1.09M1.79M963.0K2.90M
Total liabilities8.43M10.8M14.6M12.7M30.8M8.96M10.7M10.7M1.70M1.34M
Shareholders' equity9.83M11.8M-2.75M-113.0K18.2M24.4M20.9M27.9M394.0K5.20M
Shares outstanding16.1M7.30M9.81K11.4K8.10M4.25M4444

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-14.8M-17.4M-12.7M-16.8M-14.9M-7.25M-10.1M-4.24M-1.34M-3.98M
Capital spending-8.00K-298.0K0-18.0K-18.0K-3.00K-8.00K-5.68K-37.0K-77.8K
Free cash flow-14.8M-17.6M-12.7M-16.8M-15.1M-7.25M-10.1M-4.24M-1.34M-4.06M
Cash from investing-8.00K-298.0K0791.0K1.00M-3.00K229.0K1.51M-128.0K-178.7K
Cash from financing10.6M36.8M11.0M-1.31M33.8M6.03M11.2M2.42M1.16M4.31M
Dividends paid-11.0M-1.51M
Share buybacks-3.19M0-6.65M-1.51M0
Change in cash-4.18M19.1M-1.75M-17.3M19.9M-1.22M1.29M-298.6K-1.54M2.07M

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 19, 2026Current reportSEC
8-K · Current reportNov 17, 2026Material contractSEC
10-Q · Quarterly reportNov 13, 2026Quarterly reportSEC
8-K · Current reportNov 2, 2026Material contractSEC
424B5 · ProspectusOct 30, 2026Offer documentSEC
8-K · Current reportOct 30, 2026Current reportSEC
4 · Change in ownershipOct 9, 2026Insider tradeSEC
8-K · Current reportOct 1, 2026Current reportSEC
8-K · Current reportSep 29, 2026Current reportSEC
8-K · Current reportSep 16, 2026Current reportSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportSep 14, 2026Current reportSEC
8-K · Current reportAug 14, 2026ResultsSEC
10-Q · Quarterly reportAug 14, 2026Quarterly reportSEC
8-K · Current reportJul 1, 2026Meeting outcomeSEC
8-K · Current reportJun 22, 2026Current reportSEC
8-K · Current reportJun 2, 2026Management or board changeSEC
10-Q · Quarterly reportMay 15, 2026Quarterly reportSEC
4 · Change in ownershipMay 14, 2026Insider tradeSEC
4 · Change in ownershipMay 11, 2026Insider tradeSEC
3 · Initial statement of ownershipMay 11, 2026Insider tradeSEC
8-K · Current reportMay 8, 2026Current reportSEC
4 · Change in ownershipMay 7, 2026Insider tradeSEC
8-K · Current reportMay 6, 2026Current reportSEC
ARS · Annual report to shareholdersApr 30, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 30, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 30, 2026Meeting noticeSEC
4/A · Change in ownership, amendedApr 30, 2026Insider tradeSEC
4 · Change in ownershipApr 30, 2026Insider tradeSEC
8-K · Current reportApr 28, 2026Current reportSEC
424B3 · ProspectusApr 27, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveApr 27, 2026Other filingsSEC
S-3/A · Registration statement, amendedApr 24, 2026Offer documentSEC
CORRESP · Letter to the SECApr 22, 2026Other filingsSEC
8-K · Current reportApr 22, 2026Current reportSEC
PRE 14A · Preliminary proxy statementApr 10, 2026Meeting noticeSEC
8-K · Current reportApr 1, 2026ResultsSEC
10-K · Annual reportMar 30, 2026Annual reportSEC
8-K · Current reportMar 9, 2026Current reportSEC
8-K · Current reportMar 6, 2026Material contractSEC
UPLOAD · Letter from the SECFeb 19, 2026Other filingsSEC
8-K · Current reportFeb 19, 2026Current reportSEC
S-3 · Registration statementFeb 12, 2026Offer documentSEC
8-K · Current reportFeb 4, 2026Current reportSEC
424B5 · ProspectusJan 29, 2026Offer documentSEC
8-K · Current reportJan 29, 2026Material contractSEC
4 · Change in ownershipJan 16, 2026Insider tradeSEC
8-K · Current reportDec 23, 2025FinancingSEC
8-K · Current reportDec 8, 2025Management or board changeSEC
EFFECT · Notice that a registration is effectiveDec 8, 2025Other filingsSEC
CORRESP · Letter to the SECDec 4, 2025Other filingsSEC
S-3 · Registration statementDec 3, 2025Offer documentSEC
10-Q · Quarterly reportNov 14, 2025Quarterly reportSEC
4 · Change in ownershipOct 2, 2025Insider tradeSEC
EFFECT · Notice that a registration is effectiveOct 1, 2025Other filingsSEC
424B3 · ProspectusSep 30, 2025Offer documentSEC
CORRESP · Letter to the SECSep 30, 2025Other filingsSEC
UPLOAD · Letter from the SECSep 29, 2025Other filingsSEC
S-3 · Registration statementSep 25, 2025Offer documentSEC
8-K · Current reportSep 24, 2025Current reportSEC
8-K · Current reportSep 22, 2025Material contractSEC
8-K · Current reportSep 19, 2025Current reportSEC
8-K · Current reportAug 27, 2025Current reportSEC
10-Q · Quarterly reportAug 15, 2025Quarterly reportSEC
NT 10-Q · Late filing noticeAug 14, 2025Explanation requestSEC
8-K · Current reportJul 16, 2025Current reportSEC
3 · Initial statement of ownershipJul 14, 2025Insider tradeSEC
8-K · Current reportJul 7, 2025Management or board changeSEC
8-K · Current reportJul 1, 2025Current reportSEC
8-K · Current reportJun 30, 2025Current reportSEC
RW · Request to withdraw a registrationJun 24, 2025Other filingsSEC
UPLOAD · Letter from the SECJun 20, 2025Other filingsSEC
8-K · Current reportJun 17, 2025Meeting outcomeSEC
DRS · Draft registration statementJun 16, 2025Offer documentSEC
8-K · Current reportJun 11, 2025Management or board changeSEC
8-K · Current reportJun 5, 2025Current reportSEC
8-K · Current reportJun 3, 2025Current reportSEC
8-K · Current reportMay 13, 2025Current reportSEC
10-Q · Quarterly reportMay 9, 2025Quarterly reportSEC
8-K · Current reportMay 9, 2025ResultsSEC
ARS · Annual report to shareholdersApr 30, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 30, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 30, 2025Meeting noticeSEC
8-K · Current reportApr 28, 2025Current reportSEC
8-K · Current reportApr 16, 2025Management or board changeSEC
10-K · Annual reportMar 31, 2025Annual reportSEC
8-K · Current reportMar 31, 2025ResultsSEC
8-K · Current reportMar 25, 2025Current reportSEC
8-K · Current reportMar 18, 2025Current reportSEC
8-K · Current reportMar 14, 2025Current reportSEC
8-K · Current reportMar 7, 2025Current reportSEC
8-K · Current reportMar 4, 2025Current reportSEC
8-K · Current reportFeb 27, 2025Current reportSEC
8-K · Current reportFeb 25, 2025Current reportSEC
8-K · Current reportFeb 7, 2025Current reportSEC
8-K · Current reportJan 30, 2025Current reportSEC
4/A · Change in ownership, amendedJan 24, 2025Insider tradeSEC
4/A · Change in ownership, amendedJan 24, 2025Insider tradeSEC
4/A · Change in ownership, amendedJan 24, 2025Insider tradeSEC
4 · Change in ownershipJan 24, 2025Insider tradeSEC
4 · Change in ownershipJan 24, 2025Insider tradeSEC
4 · Change in ownershipJan 24, 2025Insider tradeSEC
4 · Change in ownershipJan 24, 2025Insider tradeSEC
4 · Change in ownershipJan 24, 2025Insider tradeSEC
4 · Change in ownershipJan 24, 2025Insider tradeSEC
8-K · Current reportNov 19, 2024Current reportSEC
10-Q · Quarterly reportNov 14, 2024Quarterly reportSEC
8-K · Current reportNov 14, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedNov 13, 2024Big-stake noticeSEC
8-K · Current reportOct 23, 2024Current reportSEC
8-K · Current reportOct 11, 2024Current reportSEC
8-K · Current reportOct 4, 2024Management or board changeSEC
4 · Change in ownershipOct 1, 2024Insider tradeSEC
3 · Initial statement of ownershipOct 1, 2024Insider tradeSEC
3 · Initial statement of ownershipSep 18, 2024Insider tradeSEC
8-K · Current reportSep 17, 2024Current reportSEC
8-K · Current reportSep 13, 2024Material contractSEC
8-K/A · Current report, amendedSep 10, 2024Management or board changeSEC
424B5 · ProspectusSep 9, 2024Offer documentSEC
8-K · Current reportSep 9, 2024Management or board changeSEC
S-3 · Registration statementAug 30, 2024Offer documentSEC
SCHEDULE 13G · Big-stake noticeAug 29, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeAug 29, 2024Big-stake noticeSEC
8-K · Current reportAug 21, 2024Material contractSEC
DEFR14AAug 19, 2024Meeting noticeSEC
10-Q · Quarterly reportAug 5, 2024Quarterly reportSEC
DEFA14A · Additional proxy materialJul 26, 2024Meeting noticeSEC
8-K · Current reportJul 23, 2024Current reportSEC
8-K · Current reportJul 22, 2024Current reportSEC
ARS · Annual report to shareholdersJul 1, 2024Annual reportSEC
DEF 14A · Proxy statementJul 1, 2024Meeting noticeSEC
8-K · Current reportJun 28, 2024Current reportSEC
8-K · Current reportJun 26, 2024Current reportSEC
PRE 14A · Preliminary proxy statementJun 21, 2024Meeting noticeSEC
8-K · Current reportJun 21, 2024Current reportSEC
8-K · Current reportJun 6, 2024Management or board changeSEC
8-K/A · Current report, amendedMay 24, 2024ResultsSEC
8-K · Current reportMay 21, 2024Material contractSEC
424B5 · ProspectusMay 17, 2024Offer documentSEC
8-K · Current reportMay 15, 2024ResultsSEC
424B5 · ProspectusMay 14, 2024Offer documentSEC
10-Q · Quarterly reportMay 14, 2024Quarterly reportSEC
424B5 · ProspectusMay 9, 2024Offer documentSEC
8-K · Current reportMay 9, 2024Current reportSEC
RW · Request to withdraw a registrationMay 8, 2024Other filingsSEC
8-K · Current reportMay 6, 2024Current reportSEC
424B5 · ProspectusMay 6, 2024Offer documentSEC
8-K · Current reportMay 3, 2024Current reportSEC
424B5 · ProspectusMay 2, 2024Offer documentSEC
424B5 · ProspectusMay 2, 2024Offer documentSEC
424B5 · ProspectusMay 2, 2024Offer documentSEC
8-K · Current reportApr 30, 2024Current reportSEC
10-K/A · Annual report, amendedApr 29, 2024Annual reportSEC
8-K · Current reportApr 18, 2024Current reportSEC
S-1/A · Registration statement, amendedApr 17, 2024Offer documentSEC
424B5 · ProspectusApr 15, 2024Offer documentSEC
424B5 · ProspectusApr 12, 2024Offer documentSEC
424B5 · ProspectusApr 11, 2024Offer documentSEC
424B5 · ProspectusApr 9, 2024Offer documentSEC
S-1/A · Registration statement, amendedApr 5, 2024Offer documentSEC
8-K · Current reportApr 5, 2024Current reportSEC
8-K · Current reportApr 4, 2024Meeting outcomeSEC
8-K · Current reportApr 1, 2024Current reportSEC
8-K · Current reportMar 26, 2024Current reportSEC
S-8 · Registration statement for employee plansMar 25, 2024Offer documentSEC
8-K · Current reportMar 19, 2024Material contractSEC
424B5 · ProspectusMar 19, 2024Offer documentSEC
8-K · Current reportMar 15, 2024Material contractSEC
8-K · Current reportMar 8, 2024ResultsSEC
10-K · Annual reportMar 8, 2024Annual reportSEC
DEF 14A · Proxy statementMar 7, 2024Meeting noticeSEC
8-K · Current reportMar 4, 2024Management or board changeSEC
8-K · Current reportMar 1, 2024Material contractSEC
UPLOAD · Letter from the SECFeb 27, 2024Other filingsSEC
PRER14AFeb 23, 2024Other filingsSEC
8-K · Current reportFeb 14, 2024Material contractSEC
SC 13G/A · Big-stake notice, amendedFeb 12, 2024Big-stake noticeSEC
DFeb 2, 2024Other filingsSEC
8-K · Current reportFeb 1, 2024Management or board changeSEC
PRE 14A · Preliminary proxy statementJan 26, 2024Meeting noticeSEC
8-K · Current reportJan 25, 2024Material contractSEC
8-K · Current reportJan 19, 2024Material contractSEC
S-1/A · Registration statement, amendedDec 15, 2023Offer documentSEC
8-K · Current reportDec 11, 2023Management or board changeSEC
8-K · Current reportDec 6, 2023Current reportSEC
S-1/A · Registration statement, amendedDec 6, 2023Offer documentSEC
8-K · Current reportDec 5, 2023Current reportSEC
S-1/A · Registration statement, amendedDec 4, 2023Offer documentSEC
EFFECT · Notice that a registration is effectiveNov 30, 2023Other filingsSEC
CORRESP · Letter to the SECNov 27, 2023Other filingsSEC
8-K · Current reportNov 17, 2023Current reportSEC
10-Q · Quarterly reportNov 14, 2023Quarterly reportSEC
8-K · Current reportNov 13, 2023Current reportSEC
UPLOAD · Letter from the SECNov 8, 2023Other filingsSEC
S-3 · Registration statementNov 2, 2023Offer documentSEC
S-1 · Registration statementOct 31, 2023Offer documentSEC
8-K · Current reportOct 30, 2023Current reportSEC
424B3 · ProspectusOct 23, 2023Offer documentSEC
EFFECT · Notice that a registration is effectiveOct 20, 2023Other filingsSEC
CORRESP · Letter to the SECOct 17, 2023Other filingsSEC
S-3/A · Registration statement, amendedOct 17, 2023Offer documentSEC

This page holds 200 of 406 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Allarity Therapeutics, Inc.’s releases · as of Nov 12, 2026

Common shares
15,997,108
Fully diluted
15,997,108

Fully diluted

LineSharesAs of
Common shares15,997,108Nov 12, 2026

Share count over time

CountShares
Nov 12, 202615,997,108

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Renaissance Technologies305K1.9%US$320KSep 30, 2026
Vanguard247K1.5%US$259KSep 30, 2026
Geode Capital155K0.97%US$163KSep 30, 2026
State Street155K0.97%US$163KSep 30, 2026
Focus Partners Wealth51,6280.32%US$54,209Sep 30, 2026
Northern Trust36,5340.23%US$38,361Sep 30, 2026
Hrt Financial LP33,0820.21%US$34,000Sep 30, 2026
Virtu Financial LLC26,2820.16%US$28,000Sep 30, 2026
UBS24,6200.15%US$25,851Sep 30, 2026
Citigroup Inc17,6160.11%US$18,497Sep 30, 2026
All 19 holders
HolderSharesOf the companyValueAs of
StoneX Group Inc.17,3880.11%US$18,794Sep 30, 2026
Two Sigma14,9960.09%US$15,746Sep 30, 2026
Morgan Stanley5,0000.03%US$5,250Sep 30, 2026
Tower Research Capital LLC (TRC)4,3520.03%US$4,570Sep 30, 2026
Caitong International Asset Management Co., Ltd23<0.01%US$24Sep 30, 2026
Robinhood Markets, Inc.10<0.01%US$11Sep 30, 2026
Barclays3<0.01%US$3Sep 30, 2026
Jones Financial Companies Lllp1<0.01%US$1Sep 30, 2026
Danske Bank A/S1<0.01%US$1Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Extended Market Index Fund172K1.1%US$222KJun 30, 2026
Fidelity Extended Market Index Fund94,2890.59%US$155KMay 31, 2026
Fidelity Total Market Index Fund22,1660.14%US$36,352May 31, 2026
Fidelity Series Total Market Index Fund21,5950.13%US$35,416May 31, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Gerald W McLaughlin
Other companies: Aytu BioPharma, Inc. (Director · Mar 19, 2021 – Apr 8, 2021 · Past); Neos Therapeutics Inc (Chief Executive Officer, Director · Mar 2, 2020 – Mar 19, 2021 · Past)
Director · Since at least Oct 1, 2022
David Roth
Other companies: Syros Pharmaceuticals, Inc. (Chief Medical Officer · Jun 29, 2016 – Nov 18, 2024 · Past)
Director · Jul 7, 2022 – Jul 7, 2022 · Past
Jeffrey S Ervin
Other companies: Cingulate Inc. (Director · Since at least Feb 12, 2024)
CFO · Since at least Jul 1, 2025
Jeremy R. Graff
Other companies: IN8bio, Inc. (Director · Since at least May 1, 2023)
See Remarks · Since at least Sep 30, 2024
Steve Carchedi
Other companies: Sunesis Pharmaceuticals Inc (Director · Jun 20, 2013 – Jun 30, 2020 · Past)
Chief Executive Officer, Director · Dec 20, 2021 – Dec 20, 2021 · Past
Thomas Jensen
Other companies: Valion Bio, Inc. (Director · Since at least Aug 27, 2026)
CEO · Since at least Dec 20, 2021
Alexander EpshinskyCFO · Sep 12, 2024 – Jan 22, 2025 · Past
James G CullemSVP, Chief Business Officer · Dec 20, 2021 – Dec 20, 2021 · Past
Jeff ErvinChief Financial Officer · Since at least Mar 31, 2026
Jens Erik KnudsenFormer Chief Financial Officer · Dec 20, 2021 – Jun 27, 2022 · Past
All 16 people
PersonSeat
Jerry McLaughlinChairman, Independent Board Member · Since at least Jun 11, 2025
Jesper HoeilandDirector · Since at least Jun 10, 2025
Jesper HøilandIndependent Board Member · Since at least Mar 31, 2026
Joan Yvonne BrownChief Financial Officer · Jun 29, 2022 – Jun 29, 2022 · Past
Laura BenjaminIndependent Board Member · Since at least Aug 1, 2023
Steen KnudsenChief Scientific Officer, Founder · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Allarity Therapeutics, Inc.